Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III atezolizumab plus paclitaxel, carboplatin, and bevacizumab in newly diagnosed advanced ovarian cancer
jRCT2080223474Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Atezolizumab arm with Placebo arm (2 arms). Primary endpoints: Progression-free survival (PFS) and Overall survival (OS). Started Mar 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2080223474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223474.